Skip to main content
OpenTrials

Clinical trial condition

HER2-positive Breast Cancer

Explore clinical trials studying HER2-positive Breast Cancer. Study availability and eligibility vary by location and protocol.

202 public trials 83 recruiting studies
Refine in advanced search Browse all conditions

HER2-positive Breast Cancer trial results

Active, Not Recruiting

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

NCT04569747

Conditions
Breast Cancer, Breast Diseases, Breast Neoplasms, +9 more
Locations
  • Stamford Hospital Stamford, Connecticut, United States
  • University of Miami- Sylvester Comprehensive Cancer Center Miami, Florida, United States
  • Winship Cancer Institute at Emory University Hospital Midtown Atlanta, Georgia, United States
  • Emory University - Winship Cancer Institute Atlanta, Georgia, United States
View all 32 locations
View Trial Details
Active, Not Recruiting

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

NCT03384914

Conditions
Breast Cancer Female, Breast Cancer Stage I, Breast Cancer Stage II, +16 more
Locations
  • H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States
  • Emory - Winship Cancer Institute Atlanta, Georgia, United States
  • Indiana University - Melvin and Bren Simon Cancer Center Indianapolis, Indiana, United States
  • Rutgers Cancer Institute of New Jersey New Brunswick, New Jersey, United States
View Trial Details
Active, Not Recruiting

STOP-HER2: Stopping Trastuzumab in HER2+ MBC

NCT05721248

Conditions
Breast Cancer, Breast Diseases, Breast Neoplasms, +6 more
Locations
  • Mayo Clinic Hospital Arizona Phoenix, Arizona, United States
  • Georgetown University Medical Center Washington D.C., District of Columbia, United States
  • Mayo Clinical Hospital Florida Jacksonville, Florida, United States
  • Dana-Farber Cancer Insitute Boston, Massachusetts, United States
View all 13 locations
View Trial Details
Active, Not Recruiting

Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade

NCT06068985

Conditions
Breast Cancer, Breast Diseases, Breast Neoplasms, +5 more
Locations
  • Núcleo de Oncologia da Bahia - NOB (Oncoclínicas) Salvador, Estado de Bahia, Brazil
  • Centro de Câncer de Brasília - CETTRO (Oncoclínicas) Brasília, Federal District, Brazil
  • Oncocentro Belo Horizonte (Oncoclínicas) Belo Horizonte, Minas Gerais, Brazil
  • Centro de Pesquisa Vencer & Oncoclínica Teresina, Piauí, Brazil
View all 14 locations
View Trial Details
Active, Not Recruiting

Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer

NCT03571633

Conditions
HER2-positive Breast Cancer, Operable Breast Cancer
Locations
  • Institut Sainte Catherine Avignon, France
  • CHRU Besançon Besançon, France
  • Centre de Lutte contre le Cancer Jean Perrin Clermont-Ferrand, France
  • Groupe Hospitalier Mutualiste de Grenoble Grenoble, France
View Trial Details
Active, Not Recruiting

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

NCT06328738

Conditions
Colonic Diseases, Colorectal Cancer, Colorectal Neoplasms, +13 more
Locations
  • BRCR Medical Center Inc. Plantation, Florida, United States
  • Washington University St Louis, Missouri, United States
  • NEXT Virginia Fairfax, Virginia, United States
  • Cliniques Universitaires Saint-Luc Brussels, Belgium
View all 31 locations
View Trial Details

Related conditions